The BridgeTech Program is convened and administered by Queensland University of Technology and involves a consortium of partners including medical technology companies, universities and industry associations. The BridgeTech program specialises in the commercialisation of medical technology including medical devices and diagnostics. It is the sister program to the Bridge Program, which has an emphasis on pharmaceuticals.
The BridgeTech Program will enable Australia to more effectively capitalise on its world-class medical research sector by providing entrepreneurs and scientists training and expertise on the commercialisation pathway for medical devices and diagnostics. The program has been crafted and developed in collaboration with industry partners and with leaders in key global organisations in the medical-biotechnology sector.
Launching in April 2018 the program will select 100 participants from across Australia to take part in face-to-face and online training in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to research translation and the commercialisation of medical technology.
Selected as part of the MTPConnect Project Fund Program, The BridgeTech Program has been awarded industry matched funding to deliver a unique education program that enables participants to successfully navigate the commercialisation of Australian med-tech research. A key barrier identified in MTPConnect’s draft Sector Competitiveness Plan, and addressed by the BridgeTech Program, is the lack of commercialisation skills and business acumen across researchers and life science entrepreneurs, particularly in relation to medical technology and medical devices.
The BridgeTech Program is unique in its industry-led medical technology expertise and integration into venture capital and global medical technology networks and its ability to share specific, detailed and practical translation know-how. Participants in the BridgeTech Program will gain confidence and create networks and opportunities in all areas of the commercialisation pathway.